NCT00192023 arm group f6dfb98ca3654af73de96e2cdd47b28a [clinicaltrials_resource:NCT00192023/arm-group/f6dfb98ca3654af73de96e2cdd47b28a]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00192023 arm group f6dfb98ca3654af73de96e2cdd47b28a [clinicaltrials_resource:NCT00192023/arm-group/f6dfb98ca3654af73de96e2cdd47b28a]
Bio2RDF identifier
NCT00192023/arm-group/f6dfb98ca3654af73de96e2cdd47b28a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... dfb98ca3654af73de96e2cdd47b28a
description [clinicaltrials_vocabulary:description]
atomoxetine 0.5 milligrams per ...... e receives marketing approval.
identifier
clinicaltrials_resource:NCT00192023/arm-group/f6dfb98ca3654af73de96e2cdd47b28a
title
NCT00192023 arm group f6dfb98ca3654af73de96e2cdd47b28a
@en
type
label
NCT00192023 arm group f6dfb98c ...... fb98ca3654af73de96e2cdd47b28a]
@en